Vantage Investment Advisors LLC lessened its position in Abbott Laboratories (NYSE:ABT) by 1.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,443 shares of the healthcare product maker’s stock after selling 1,209 shares during the period. Vantage Investment Advisors LLC’s holdings in Abbott Laboratories were worth $5,000,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Rowland & Co. Investment Counsel ADV acquired a new position in Abbott Laboratories during the fourth quarter worth approximately $102,000. Icon Wealth Partners LLC acquired a new position in Abbott Laboratories during the fourth quarter worth approximately $102,000. SWS Partners purchased a new stake in Abbott Laboratories during the fourth quarter worth approximately $104,000. Cerebellum GP LLC purchased a new stake in Abbott Laboratories during the fourth quarter worth approximately $133,000. Finally, We Are One Seven LLC purchased a new stake in Abbott Laboratories during the fourth quarter worth approximately $138,000. 71.63% of the stock is owned by institutional investors and hedge funds.
In other Abbott Laboratories news, SVP Sharon J. Bracken sold 2,150 shares of the stock in a transaction on Friday, May 4th. The shares were sold at an average price of $58.56, for a total transaction of $125,904.00. Following the transaction, the senior vice president now directly owns 43,990 shares in the company, valued at approximately $2,576,054.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Daniel Gesua Sive Salvadori sold 3,000 shares of the stock in a transaction on Friday, May 18th. The shares were sold at an average price of $61.20, for a total transaction of $183,600.00. Following the transaction, the insider now owns 95,581 shares in the company, valued at $5,849,557.20. The disclosure for this sale can be found here. Insiders have sold a total of 5,999 shares of company stock worth $359,901 over the last quarter. 0.74% of the stock is currently owned by insiders.
Shares of Abbott Laboratories opened at $61.94 on Friday, Marketbeat.com reports. The firm has a market capitalization of $108.26 billion, a PE ratio of 24.78, a PEG ratio of 1.77 and a beta of 1.51. The company has a quick ratio of 1.24, a current ratio of 1.66 and a debt-to-equity ratio of 0.67. Abbott Laboratories has a twelve month low of $47.83 and a twelve month high of $64.60.
Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, April 18th. The healthcare product maker reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.01. The business had revenue of $7.39 billion during the quarter, compared to the consensus estimate of $7.28 billion. Abbott Laboratories had a net margin of 1.67% and a return on equity of 14.54%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.48 earnings per share. research analysts predict that Abbott Laboratories will post 2.86 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 15th. Shareholders of record on Friday, July 13th will be paid a dividend of $0.28 per share. The ex-dividend date is Thursday, July 12th. This represents a $1.12 dividend on an annualized basis and a yield of 1.81%. Abbott Laboratories’s dividend payout ratio (DPR) is 44.80%.
ABT has been the subject of several research reports. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $67.00 price objective for the company in a research note on Friday, April 20th. BTIG Research reiterated a “hold” rating on shares of Abbott Laboratories in a research note on Sunday, April 22nd. Citigroup decreased their price objective on shares of Abbott Laboratories from $66.00 to $65.00 and set a “neutral” rating for the company in a research note on Tuesday, April 24th. Finally, ValuEngine upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Four investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $69.13.
Abbott Laboratories Company Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.